A risk score for No reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention

Clinical Cardiology

Volumn 38, Issue 4, 2015, Pages 208-215

  Wang, Jin Wen ^a   Zhou, Zi Qiang ^b   Chen, Yun Dai ^c   Wang, Chang Hua ^a   Zhu, Xiao Ling ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLUCOSE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ADULT; AGE; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE ASSESSMENT; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY STENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INDEPENDENT VARIABLE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL COUNT; NO REFLOW PHENOMENON; PAIN; PERCUTANEOUS CORONARY INTERVENTION; PRE PERCUTANEOUS CORONARY INTERVENTION THROMBUS SCORE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; VALIDATION STUDY; AGED; CLINICAL TRIAL; HEART MUSCLE REVASCULARIZATION; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE;

EID: 84928433068     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22376     Document Type: Article

References (25)

1. Keeley EC, Boura JA, Grines CL,. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20.
2. Gibson CM, Cannon CP, Murphy SA, et al. TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002; 105: 1909-1913.
3. Rezkalla SH, Kloner RA,. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72: 950-957.
4. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994; 89: 2514-2518.
5. Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007; 99: 442-445.
6. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004; 109: 1121-1126.
7. Cura FA, L'Allier PL, Kapadia SR, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001; 88: 124-128.
8. Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002; 122: 1322-1332.
9. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003; 41: 1-7.
10. Kirma C, Izgi A, Dundar C, et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J. 2008; 72: 716-721.
11. Su Q, Li L, Liu Y,. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2013; 36: E11-E16.
12. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med. 1985; 312: 932-936.
13. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001; 103: 2550-2554.
14. van 't Hof AW, Liem A, Suryapranata H, et al. Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998; 97: 2302-2306.
15. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009; 54: 281-292.
16. Takahashi T, Hiasa Y, Ohara Y, et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol. 2007; 100: 35-40.
17. Turschner O, D'hooge J, Dommke C, et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J. 2004; 25: 794-803.
18. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation. 2000; 102: 3111-3116.
19. 2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol. 2001; 280: H2649-H2657.
20. Madjid M, Awan I, Willerson JT, et al. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004; 44: 1945-1956.
21. Turner SJ, Ketch TR, Gandhi SK, et al. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J. 2008; 155: 806-816.
22. O'Donoghue M, Morrow DA, Cannon CP, et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J. 2008; 29: 984-991.
23. Desch S, Eitel I, Schmitt J, et al. Effect of coronary collaterals on microvascular obstruction as assessed by magnetic resonance imaging in patients with acute ST-elevation myocardial infarction treated by primary coronary intervention. Am J Cardiol. 2009; 104: 1204-1209.
24. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001; 104: 636-641.
25. Nakamura T, Kubo N, Ako J, et al. Angiographic no-reflow phenomenon and plaque characteristics by virtual histology intravascular ultrasound in patients with acute myocardial infarction. J Interv Cardiol. 2007; 20: 335-339.